Top Healthcare Stocks by UQS Score

1151 stocks scored · Last updated October 7, 2026

Healthcare is one of the few sectors where demand is structurally guaranteed — aging populations, chronic disease prevalence, and innovation-driven treatment cycles create persistent tailwinds regardless of economic conditions. But the sector spans an enormous range: from cash-burning biotech startups hoping for FDA approval to diversified pharma giants with decades of patent-protected revenue. The UQS model cuts through this noise by scoring actual financial performance and balance sheet health, not pipeline potential. Companies ranked highest here have already demonstrated they can turn scientific innovation into profitable, sustainable businesses.

Healthcare Sector Characteristics

Healthcare encompasses pharmaceuticals, biotechnology, medical devices, managed care, hospital systems, and life science tools. What makes the sector unique for scoring is its bimodal distribution: large pharma companies tend to have exceptional quality scores (high margins from patented drugs) but modest growth scores (patent cliffs create revenue headwinds), while smaller biotech companies show the inverse pattern. Medical device companies often hit a sweet spot — consistent revenue growth with defensible market positions and recurring consumable revenue. The UQS model captures these dynamics by scoring each metric independently, so a pharma company isn't penalized for slow growth if it excels everywhere else.

Scoring note: Healthcare uses consumer-sector thresholds (25% ROIC, 30% operating margin) because pharmaceutical margins vary widely depending on patent cliffs and R&D spending cycles. Biotech companies with negative earnings can still score well on growth and moat if they have strong pipelines and low debt.

Healthcare Sector Score Overview

61

Avg UQS Score

67

Avg Quality

39

Avg Moat

57

Avg Growth

78

Avg Risk

77

Avg Valuation

Top Healthcare Stocks: Who Leads and Why

#1GLPG.ASLakefront Biotherapeutics71

Lakefront Biotherapeutics leads healthcare with a 71 UQS score, driven by a 65 quality rating that reflects superior margins and capital returns. Its moat score of 50 confirms deep competitive advantages in its therapeutic areas.

#2CPH.TOCipher Pharmaceuticals Inc.66

Cipher Pharmaceuticals Inc. scores 66 overall, balancing strong profitability (quality: 86) with a robust balance sheet (risk: 84). A well-diversified revenue base supports scoring consistency.

#3PLXProtalix BioTherapeutics, Inc.64

At 64, Protalix BioTherapeutics, Inc. earns the third spot with notable strength in valuation (66) — suggesting the market may be underpricing its fundamentals relative to the quality of the business.

#4CCLDCareCloud, Inc.63

CareCloud, Inc. scores 63 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

#5INVAInnoviva, Inc.63

Innoviva, Inc. scores 63 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

Full Healthcare Ranking: Top 25 Stocks

#	Stock	UQS	Q	M	G	R	V
1	GLPG.ASLakefront Biotherapeutics	71	65	50	61	100	99
2	CPH.TOCipher Pharmaceuticals Inc.	66	86	30	70	84	71
3	PLXProtalix BioTherapeutics, Inc.	64	89	27	51	97	66
4	CCLDCareCloud, Inc.	63	66	35	58	75	100
5	INVAInnoviva, Inc.	63	68	36	44	86	100
6	KMDAKamada Ltd.	62	44	38	70	100	85
7	SIGASIGA Technologies, Inc.	62	72	25	52	82	100
8	RHHBYRoche Holding AG	62	91	52	40	54	67
9	LNTHLantheus Holdings, Inc.	61	77	46	36	85	71
10	IRWDIronwood Pharmaceuticals, Inc.	61	83	24	61	50	100
11	BWAYBrainsWay Ltd.	61	49	41	94	85	48
12	VCYTVeracyte, Inc.	61	57	41	80	82	53
13	SNYSanofi	61	64	50	49	58	91
14	NVSNovartis AG	60	85	50	48	39	73
15	LKFTLakefront Biotherapeutics N.V.	60	70	50	0	100	100
16	TCMDTactile Systems Technology, Inc.	60	52	36	60	100	73
17	VMDViemed Healthcare, Inc.	60	52	31	90	76	66
18	ABUSArbutus Biopharma Corp	60	73	11	44	100	100
19	JNJJohnson & Johnson	59	78	53	46	63	53
20	BMYBristol-Myers Squibb Company	59	84	47	42	27	92
21	OPRXOptimizeRx Corp.	59	54	29	61	76	98
22	INDVIndivior Pharmaceuticals Inc	59	66	44	49	59	83
23	PENPenumbra, Inc.	59	52	45	81	100	21
24	EWEdwards Lifesciences Corporation	58	61	53	50	82	50
25	VHI.TOVitalhub Corp.	58	30	35	100	93	56

Filter all 1151+ healthcare stocks in the full directory

Browse All Stocks

Frequently Asked Questions About Healthcare Stocks

How does UQS handle biotech companies with no revenue?

Pre-revenue biotech companies typically score low overall because most UQS metrics require financial data (revenue, margins, earnings). Their quality score will be near zero, and growth metrics that depend on trailing revenue won't have data. However, if a biotech has low debt and strong cash reserves, it can score reasonably on risk. The moat score, being AI-driven, can also recognize strong IP portfolios and regulatory moats even for pre-revenue companies.

Why do healthcare stocks often score high on quality?

Pharmaceutical companies with patent-protected drugs enjoy some of the highest margins in the market — gross margins of 70-80% are common. Patents create temporary monopolies that allow premium pricing, and the regulatory approval process creates enormous barriers to entry. These structural advantages directly translate into high ROIC, wide operating margins, and strong free cash flow generation — exactly what the quality pillar measures.

What impact do patent cliffs have on UQS scores?

Patent expiration directly affects growth scores as revenue from blockbuster drugs declines. Quality scores may also dip as margins compress from generic competition. However, well-managed pharma companies with diversified pipelines often maintain their overall UQS scores by replacing expiring revenue with new drug launches. The three-year revenue CAGR in the growth pillar helps distinguish between transient patent cliff effects and structural decline.